- Edwards SAPIEN 3
- (balloon expansion)
TAVI was applied clinically for the first time in the world in 2002, and in October 2009 we implemented TAVI for the first time in Japan. Since then, our facility has participated in trials of all TAVI valves, and employed the most advanced
medical care to provide the same treatment for chronic dialysis patients and others.
Since being approved for insurance coverage in 2013, TAVI has been actively employed for patients with a high risk indicated for open-heart surgery, and since 2014 the number of cases has been about 100 per year. With the cumulative number of cases exceeding 420 at the end of 2016, our institution boasts the largest number in Japan. Including those currently undergoing clinical trials, there are now four types of TAVI valve available, and one characteristic of our facility is the ability to select from a range of options the most suitable valve for each patient.
TAVI at our hospital:
Regarding TAVI, 30 day mortality is 0.80%, which is no worse than open heart surgery (subjects with average age of 82.7 years, STS score of 10.1%). There have been no surgical death cases since 2015, and the home discharge rate is around 90%, which leads us to consider this a treatment that can maintain the patient's quality of life.
These good results are all thanks to the staff of this facility, and their abundant experience in medical treatment. We have three certified TAVI supervisors, and two staff members who have trained with state-of-the-art TAVI valve therapy in
In the future, minimally-invasive treatment using a catheter is expected to contribute not only for the aortic valve but also in other heart valves in the future. We will continue to provide patients with high-quality medical treatment, supporting society with state-of-the-art medical technology to ensure patients' safety and peace of mind . Click here for more details on TAVI